Posted by admin on Aug 8th, 2022
Surgalign (NASDAQ:SRGA – Get Rating) will be posting its quarterly earnings results after the market closes on Tuesday, August 9th. Surgalign has set its FY 2022 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.
Surgalign (NASDAQ:SRGA – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($2.40) EPS for the quarter. The firm had revenue of $20.61 million for the quarter. Surgalign had a negative net margin of 79.07% and a negative return on equity of 169.33%.
Shares of Surgalign stock opened at $4.00 on Monday. The company has a current ratio of 3.57, a quick ratio of 2.76 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $26.47 million, a P/E ratio of -0.25 and a beta of 2.16. The business has a fifty day simple moving average of $3.67 and a two-hundred day simple moving average of $8.86. Surgalign has a 12 month low of $2.95 and a 12 month high of $48.60.
In related news, CFO David Lyle purchased 19,000 shares of the stock in a transaction dated Wednesday, May 18th. The stock was purchased at an average price of $5.26 per share, with a total value of $99,940.00. Following the transaction, the chief financial officer now directly owns 59,000 shares in the company, valued at $310,340. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.30% of the company’s stock.
Several large investors have recently modified their holdings of SRGA. Group One Trading L.P. raised its position in shares of Surgalign by 55.8% in the 1st quarter. Group One Trading L.P. now owns 249,066 shares of the company’s stock worth $76,000 after purchasing an additional 89,200 shares during the last quarter. Northern Trust Corp raised its position in Surgalign by 52.9% in the 1st quarter. Northern Trust Corp now owns 358,662 shares of the company’s stock worth $109,000 after buying an additional 124,055 shares during the last quarter. Verition Fund Management LLC raised its position in Surgalign by 208.7% in the 1st quarter. Verition Fund Management LLC now owns 459,560 shares of the company’s stock worth $140,000 after buying an additional 310,676 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Surgalign in the 1st quarter worth about $181,000. Finally, HighTower Advisors LLC raised its position in Surgalign by 24.9% in the 1st quarter. HighTower Advisors LLC now owns 1,003,500 shares of the company’s stock worth $305,000 after buying an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 28.35% of the company’s stock.
Surgalign Holdings, Inc, a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine.
Receive News & Ratings for Surgalign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgalign and related companies with MarketBeat.com's FREE daily email newsletter.
Maiden (MHLD) to Release Quarterly Earnings on Tuesday
New York State Common Retirement Fund Increases Stock Position in National Vision Holdings, Inc. (NASDAQ:EYE)